These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 23173065)
1. Phosphodiesterases as therapeutic targets for Alzheimer's disease. García-Osta A; Cuadrado-Tejedor M; García-Barroso C; Oyarzábal J; Franco R ACS Chem Neurosci; 2012 Nov; 3(11):832-44. PubMed ID: 23173065 [TBL] [Abstract][Full Text] [Related]
2. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928 [TBL] [Abstract][Full Text] [Related]
3. FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects. Guo H; Cheng Y; Wang C; Wu J; Zou Z; Niu B; Yu H; Wang H; Xu J Neuropharmacology; 2017 Apr; 116():260-269. PubMed ID: 28065587 [TBL] [Abstract][Full Text] [Related]
4. The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: A systematic review of animal studies. El-Bakly W; Wagdy O; Sobhy A; Abo Elenain O; Riad MS; El Sayed M; Tarkhan S; Yassen M; Mahmoud A; Bassiony M; Nabil N Behav Brain Res; 2019 Oct; 372():112004. PubMed ID: 31163203 [TBL] [Abstract][Full Text] [Related]
5. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats. Cheng YF; Wang C; Lin HB; Li YF; Huang Y; Xu JP; Zhang HT Psychopharmacology (Berl); 2010 Oct; 212(2):181-91. PubMed ID: 20640406 [TBL] [Abstract][Full Text] [Related]
7. Neoline Improves Memory Impairment and Reduces Amyloid-β Level and Tau Phosphorylation Through AMPK Activation in the Mouse Alzheimer's Disease Model. Liu QF; Kanmani S; Lee J; Kim GW; Jeon S; Koo BS J Alzheimers Dis; 2021; 81(2):507-516. PubMed ID: 33814448 [TBL] [Abstract][Full Text] [Related]
8. The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling. Wang G; Chen L; Pan X; Chen J; Wang L; Wang W; Cheng R; Wu F; Feng X; Yu Y; Zhang HT; O'Donnell JM; Xu Y Oncotarget; 2016 Apr; 7(14):17380-92. PubMed ID: 26980711 [TBL] [Abstract][Full Text] [Related]
9. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease. Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830 [TBL] [Abstract][Full Text] [Related]
10. Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease. Gulisano W; Tropea MR; Arancio O; Palmeri A; Puzzo D Neuropharmacology; 2018 Aug; 138():151-159. PubMed ID: 29885420 [TBL] [Abstract][Full Text] [Related]
11. [Therapy of Alzheimer disease]. Kovács T Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816 [TBL] [Abstract][Full Text] [Related]
12. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects. Feng H; Wang C; He W; Wu X; Li S; Zeng Z; Wei M; He B Metab Brain Dis; 2019 Apr; 34(2):583-591. PubMed ID: 30610438 [TBL] [Abstract][Full Text] [Related]
13. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Caccamo A; Maldonado MA; Bokov AF; Majumder S; Oddo S Proc Natl Acad Sci U S A; 2010 Dec; 107(52):22687-92. PubMed ID: 21149712 [TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. Heckman PR; Wouters C; Prickaerts J Curr Pharm Des; 2015; 21(3):317-31. PubMed ID: 25159073 [TBL] [Abstract][Full Text] [Related]
15. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. Fan SJ; Huang FI; Liou JP; Yang CR Cell Death Dis; 2018 May; 9(6):655. PubMed ID: 29844403 [TBL] [Abstract][Full Text] [Related]
16. Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice. Van der Jeugd A; Parra-Damas A; Baeta-Corral R; Soto-Faguás CM; Ahmed T; LaFerla FM; Giménez-Llort L; D'Hooge R; Saura CA Sci Rep; 2018 Apr; 8(1):6431. PubMed ID: 29691439 [TBL] [Abstract][Full Text] [Related]
17. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378 [TBL] [Abstract][Full Text] [Related]
19. Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron. Saeedi M; Rashidy-Pour A Biomed Pharmacother; 2021 Jan; 133():110995. PubMed ID: 33232931 [TBL] [Abstract][Full Text] [Related]